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The high abortion rate of 45,X embryos indicates that patients with Turner syndrome and 45,X karyotype could be mosaics, in
at least one phase of embryo development or cellular lineage, due to the need for the other sex chromosome presence for
conceptus to be compatible with life. In cases of structural chromosomal aberrations or hidden mosaicism, conventional
cytogenetic techniques can be ineffective and molecular investigation is indicated. Two hundred and fifty patients with Turner
syndrome stigmata were studied and 36 who had female genitalia and had been cytogenetically diagnosed as having “pure” 45,X
karyotype were selected after 100 metaphases were analyzed in order to exclude mosaicism and the presence of genomic Y-
specific sequences (SRY, TSPY, and DAZ) was excluded by PCR. Genomic DNA was extracted from peripheral blood and
screened by the human androgen receptor (HUMARA) assay. The HUMARA gene has a polymorphic CAG repeat and, in the
presence of a second chromosome with a different HUMARA allele, a second band will be amplified by PCR. Additionally, the
CAG repeats contain two methylation-sensitive HpaII enzyme restriction sites, which can be used to verify skewed inactivation.
Twenty-five percent (9/36) of the cases showed a cryptic mosaicism involving a second X and approximately 14% (5/36), or 55%
(5/9) of the patients with cryptic mosaicism, also presented skewed inactivation. The laboratory identification of the second X
chromosome and its inactivation pattern are important for the clinical management (hormone replacement therapy, and inclusion
in an oocyte donation program) and prognostic counseling of patients with Turner syndrome.
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Introduction
The Ullrich-Turner syndrome or Turner syndrome (TS)
is defined as the combination of phenotypic features and
complete or partial absence of one of the X chromosomes,
frequently accompanied by cell line mosaicism, in women.
About 99% of the cases where 45,X is present at the time
of human conception, a natural miscarriage occurs in the
first stages of embryonic development (1). This has led to
the widely held hypothesis that, in order to be viable, a 45,X
conceptus must possess another cell line, at least in some
critical organs or at a critical period during embryogenesis
(1,2). For this reason, many females with TS stigmata who
have been ascribed a non-mosaic 45,X karyotype after
cytogenetic analysis of a limited number of cells may, in
fact, be mosaics (3). In addition to occult mosaicism, other
factors affecting the phenotype have not yet been fully
elucidated, including genomic imprinting or anomalous X
inactivation, leading to difficulties in diagnosis and genetic
counseling (4).
In mammals, X-inactivation (XI) silences one of the two
female X chromosomes and is associated with a series of
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epigenetic modifications in the inactive X, including DNA
methylation, and histone modifications (5,6). In addition,
the inactive X chromosome condenses into the Barr body
and becomes late replicated during the S phase. At the
initiation of XI in early embryogenesis, XIST RNA (XIST in
human and Xist in mouse) becomes stable and coats the
inactive X in cis (7,8). Adding further to the curiosities of XI
is the discovery that Xist is regulated in cis by an antisense
gene (Tsix) expression, which blocks the accumulation of
Xist RNA along the future active X (Xa). Studies have
shown the presence of an insulator and transcription fac-
tor, CTCF, as a candidate trans-acting factor for X chromo-
some selection in the mouse (9). If both X chromosomes
are intact in a female, the choice of which one becomes
inactivated is usually random. However, if one chromo-
some is structurally abnormal, it is typically inactivated in a
majority of cells in the adult. If one X containing XIST is
involved in a balanced translocation with an autosome, the
normal X is usually inactivated, whereas the abnormal X is
inactivated in some unbalanced translocations (10). Struc-
tural defects that delete XIST result in the failure of X
inactivation (7).
Understanding the inactivation process makes it pos-
sible to study the existence or absence of a second X
chromosome in patients with 45,X karyotype (11). The
human androgen receptor (HUMARA) gene, mapped on
Xq12, has a polymorphic CAG repeat with 87% heterozy-
gosity. In the presence of a second chromosome with a
different HUMARA allele, the second band will be ampli-
fied by PCR. The CAG repeats contain two methylation-
sensitive HpaII enzyme restriction sites. In the HUMARA
assay, prior to PCR amplification, genomic DNAs are
digested with HpaII (Figure 1) (11). The HUMARA assay
was used to detect low-level mosaicism involving X chro-
mosomes in 45,X patients.
Patients and Methods
Patients
The study was approved by the Research Ethics Com-
mittee of the Clinical Hospital of the School of Medicine of
Ribeirão Preto, University of São Paulo. The medical
records from 1991 to 2005 of 250 patients with TS stigmata
and female genitalia were reviewed, and the cases with
45,X karyotype were selected, after 100 metaphases were
analyzed in order to exclude mosaicism (12). These pa-
tients were investigated for Y-specific sequences (SRY,
TSPY and DAZ ) in peripheral blood by Bartmann et al.
(13) and by us (data not shown) and 36 patients were
considered 45,X and Y-negative. In addition, four normal
men (negative controls) and four normal women (positive
controls) were included.
Molecular genetic analysis
Genomic DNA was isolated from peripheral blood (14).
A modified HUMARA assay from Yorifuji et al. (11) was
carried out to detect X chromosome mosaicism. Prior to
PCR, the DNA samples were digested with HpaII in 10 µL,
overnight at 37°C. Aliquots (1 µL) of the digested DNA
were used to amplify the segment spanning the CAG
repeats in the HUMARA gene. The sequences of the
primers were as follows: forward primer (HUMARA-1) 5'-
TCCAGAATCTGTTCCAGAGCGTGC-3'; reverse primer
(HUMARA-2) 5'-GCTGTGAAGGTTGCTGTTCCTCAT-3'.
The PCR products were diluted 1000-fold in distilled water
and 1-µL aliquots were used for the second cycle of nested
PCR. The second set of primers was: 5'-GTGCGCGAAGT
GATCCAGAA-3' (HUMARA-3) and 5'-CCAGGACCAGG
TAGCCTGTG-3' (HUMARA-4). For band pattern compar-
ison, the results with and without HpaII digestion were run
side by side on electrophoresis gel for each patient. The
DNA of normal men and women was also used. PCR was
performed in 25 µL and the products were analyzed by
electrophoresis through 10% polyacrylamide gels and
stained with silver nitrate.
Figure 1. HUMARA assay. When an X chromosome is inactive,
these HpaII sites are methylated (oblong circles) and are resis-
tant to digestion, and subsequent PCR yields products of the
expected size (left side of the figure). However, when an X
chromosome is active, these HpaII sites are not methylated
(inverted triangles without oblong circles) and are susceptible to
HpaII digestion and, consequently, PCR amplification fails to
yield products (right side of the figure) (Modified from Ref. 11).
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Results
The data for mosaicism involving a second X chromo-
some indicate that 25% (9/36) had a second X chromo-
some and 14% (5/36), or 55% (5/9) of the patients with
cryptic mosaicism, also presented skewed inactivation
(Table 1).
Discussion
Several studies have been carried out to detect X
cryptic mosaicism in cytogenetically 45,X cases. The fre-
quency reported varies from 0-75% (Table 2) (1,3,11,15-
23) and in most cases a second X chromosome was
detected, but skewed inactivation is not. Although periph-
eral blood may not represent the rest of the tissues of the
body, analysis of samples of other tissues usually depends
on invasive procedures. In the study of Yorifuji et al. (11),
11% (2/18) of the patients with 45,X karyotype were posi-
tive for X chromosome mosaicism using the HUMARA
assay. For these authors, the detection limit was one in
960 cells (11), and we have used the same detection limit.
Different numbers of metaphases have been analyzed
to identify the karyotype as a “pure” 45,X (Table 2). It
should be noted that in our study 100 metaphases from
each patient were analyzed by conventional cytogenetics,
in order to detect chromosomic mosaicism equal or supe-
rior to 3% with a confidence interval of 0.90 or 5% with a
confidence interval of 0.99 (12). The number of cells ana-
lyzed by us was greater than reported for other studies, in
which the maximum number of metaphases analyzed was
usually up to 50 cells. Therefore, the sample used in the
present study was very carefully selected and a very small
number of informative cases were considered. Neverthe-
less, in 25% (9/36) of these cases the HUMARA assay
revealed the presence of X cryptic mosaicism (Figure 2).
The choice of which X chromosome becomes inacti-
vated is usually a random process. However, if one X
chromosome is structurally abnormal it is skewed inacti-
Table 2. Reports of cryptic mosaicism involving a second X chromosome in patients with Turner syndrome.
Reference Method Cells analyzed/patient (N) Subjects with 45,X studied Second X (%)
Hassold et al. (1) Cytog/PCR 4 to 120 31 abortions, 5 liveborns 5.5
Mathur et al. (15) Cytog/Southern blot ≥25 25 patients 0
Gicquel et al. (16) Cytog/Southern blot 4 to 50 29 patients 3.5
Hassold et al. (17) Cytog/Southern blot 3 to 80 27 abortions, 10 liveborns 10.8
Larsen et al. (3) Cytog/Southern blot ≥50 40 patients 15
Jacobs et al. (18) Cytog/PCR 100 84 patients 2.4
Yorifuji et al. (11) Cytog/HUMARA >20 18 patients 11
Nazarenko et al. (19) Cytog/FISH ≥29 (Cytog) 21 patients 42.8
200 to 1007 (FISH)
Fernández-García et al. (20) Cytog/FISH 30 (Cytog) 16 patients 75
254 to 1326 (FISH)
Hanson et al. (21) Cytog/FISH 10 to 68 (Cytog) 23 patients 43
161 to 313 (FISH)
Monroy et al. (22) Cytog/PCR 100 10 patients 0
Wiktor and Van Dyke (23) Cytog/FISH ≥30 (Cytog) 22 patients 14
500 (FISH)
Present study Cytog/HUMARA 100 36 patients 25
Cytog = conventional cytogenetics analysis; HUMARA = human androgen receptor assay; FISH = fluorescence in situ hybridization
analysis; PCR = polymerase chain reaction with other X chromosome markers; Second X (%) = cases with a second X chromosome.
Table 1. Results of the molecular analysis of 36 patients with
karyotype 45,X [100].
Number of X molecular analysis
patients
Without HpaII With HpaII Results
20 1 1 NI
7 1 0 NI
4 1 2 (=) XM
3 1* 1* XM/SI
1 1 2 (>/<) XM/SI
1 2 (</>) 1 (>) XM/SI
One hundred metaphases of each patient were analyzed. NI =
not informative for mosaicism and skewed inactivation; SI =
skewed inactivation; XM = X chromosome mosaicism; *with and
without digestion giving different band patterns; 0, 1, and 2 in the
columns HpaII show the number of bands; (>) = band of greater
intensity; (<) = band of lower intensity; (=) = bands of equal
intensity.
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vated in the majority of cells in the adult (19). Although it is
a semi-quantitative test in the way that it was carried out
here (an automated sequencer for the analysis was not
used), 55% (5/9) of the cases of X cryptic mosaicism also
revealed the presence of skewed inactivation, showing the
possible presence of a second structurally altered X chro-
mosome that was selectively inactivated and amplified
(Figure 2).
We used the HUMARA assay for the detection of low-
level mosaicism in TS for several reasons. First, the locus
is located at Xq12 (between the centromere and the X-
inactivation center at Xq13) and a structurally abnormal X
chromosome would probably retain the locus. Second,
since the locus is highly polymorphic (percentage het-
erozygosity is about 87-90%), the chance of the second X
chromosome having a different allele is high. Third, it has
been shown in TS that the structurally abnormal X chromo-
some is inactivated selectively and will be amplified selec-
tively. Even in patients with 45,X/46,XX karyotype, the
allele of the second X will be more efficiently amplified,
since X chromosomes in 46,XX cells are randomly inacti-
vated; therefore, both alleles will be equally amplified,
even in the presence of a large excess of 45,X cells (11).
In the remaining patients (27/36), the allele of a second
X chromosome was not detected by the HUMARA assay.
In seven (7/27) of these cases no band was visualized after
enzyme digestion, possibly due to the complete digestion
of the material by the restriction enzyme. This indicated
that these patients could be “pure” 45,X in peripheral
blood, with the probability of other lineages in other tis-
sues, or of being mosaics 45,X/46,XY. The last hypothesis
was excluded (Araújo A, Ramos ES, unpublished data)
and Bartmann et al. (13), at least in peripheral blood, using
PCR for Y-specific sequences. Twenty cases (20/27) were
not informative, because they all presented the same band
after digestion with HpaII. The reason for this phenomenon
could be due to incomplete digestion with the enzyme
HpaII (11). Another explanation is the presence of ho-
mozygote individuals in the sample studied or the pres-
ence of alleles with a very close band pattern, due to a
small difference in the number of repetitive CAG between
them. However, these samples could be “pure” 45,X in
peripheral blood, with other lineages in different tissues, or
45,X/46,XY, excluded in the blood by PCR using Y-specific
sequences. Some other cases which are not informative
could be explained by uniparental isodisomy of the original
X chromosome (both of the X chromosomes would have
the same allele and therefore would not be identified) (11).
The reagents and equipment used in the present study
can be found in the majority of hospitals and the HUMARA
test could be included in routine clinical investigation. The
sensitivity was high and the HUMARA assay, as used
here, could be used in association with the PCR (using Y-
specific sequences) and cytogenetic analysis (conven-
tional and molecular). The laboratory identification of the
presence of the second X chromosome and its pattern of
inactivation, associated with the exclusion of the Y chro-
mosome, are important for the clinical management and
prognostic counseling of patients with TS.
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Figure 2. Results of HUMARA nested PCR amplification visual-
ized on a 10% polyacrylamide gel electrophoresis stained with
silver nitrate. M1 and M2 = Normal men DNA without prior
digestion with HpaII (only one band corresponding to the pres-
ence of one X chromosome); W = normal woman DNA without
prior digestion with HpaII (two bands corresponding to the pres-
ence of two X chromosomes); Wd = DNA from a normal woman
with prior digestion with HpaII (two bands corresponding to the
presence of two X chromosomes inactivated, showing the fe-
male natural mosaicism for the X-inactivation); P = DNA from a
patient with karyotype 45,X [100] (a strong and a very weak
band, showing a positive result for cryptic X chromosome mosa-
icism); Pd = DNA from a patient (P) treated with HpaII (only one
band showing a skewed inactivation); Mar = molecular marker
(100 bp). One hundred metaphases of each patient were ana-
lyzed.
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